RTW forms Prolium to develop Keymed Biosciences' CD20×CD3 bispecific CM355 outside Asia for $17.5M upfront, part of growing ...

CMS didn't wait for President-elect Donald Trump to take office before issuing its second list of drugs to be negotiated ...

Welcome back to the new and improved Endpoints Weekly! This week we’ll be recapping the JP Morgan Healthcare Conference, IRA ...

Sage Therapeutics has sued Biogen in Delaware court, one week after receiving a $469 million buyout offer from the larger neuroscience pharma company.

Spark co-founder Kathy High made a quiet return to eye disease drug development, becoming CEO of US-Swiss biotech RhyGaze ...

Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare ...

FDA approves AstraZeneca's Calquence as first BTK inhibitor for first-line mantle cell lymphoma, leading BeiGene's Brukinsa ...

NeurIPS, the biggest AI research conference, turned Vancouver’s convention center into a battleground for wooing AI talent.

The rise of GLP-1s have made treating obesity one of the largest market opportunities in history. It also has reinforced a ...

FDA approves Amgen's Lumakras with Vectibix for metastatic colorectal cancer with KRAS G12C mutation, based on Phase 3 ...

The EMA's human medicines committee recommended 114 medicines for approval in 2024, marking the highest number of positive ...

Novo Nordisk's high-dose Wegovy shows 20.7% weight loss in Phase 3 but falls short of Eli Lilly's Zepbound, raising questions ...